On March 14, 2023, Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, announced its launch following $52 million of financing. The company’s Series A was co-led by Insight Partners and UCB Ventures. Existing investors Upfront Ventures and BOLD Capital Partners and new investors Eli Lilly and Company, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, PhiFund Ventures, and others also participated in the financing. Wilson Sonsini Goodrich & Rosati advised Switch Therapeutics on the transaction and launch.

The funds raised will be used to select and advance a development candidate for Switch’s lead program for the treatment of a central nervous system disease and recruit talent to accelerate the company’s growth. The company also intends to explore opportunities to expand its CASi platform into new areas through potential pharmaceutical collaborations.

The Wilson Sonsini team that advised Switch Therapeutics included:

Corporate
Ken Clark
Christina Poulsen
Andrew Collins
Lucas Baker

Employee Benefits
Michelle Wallin

Technology Transactions
David Pirko

For more information, please see Switch Therapeutics' press release.